Trial Profile
A Pilot Study of Belimumab (Benlysta) for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Belimumab (Primary) ; Cyclophosphamide; Methotrexate; Tacrolimus
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 10 Oct 2022 Planned End Date changed from 30 Sep 2024 to 9 Feb 2024.
- 10 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 16 May 2022 Planned End Date changed from 31 Mar 2024 to 30 Sep 2024.